Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Elliott

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Reproduction (Cambridge, England)|November 11, 2008
Effects of HSPA8, an evolutionarily conserved oviductal protein, on boar and bull spermatozoaRoslyn M A Elliott, Rhiannon E Lloyd, Alireza Fazeli, et al.
Bone Marrow Transplantation|July 16, 2008
Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancyL J Costa, V Rodriguez, L F Porrata, et al.
Magma (New York, N.Y.)|June 1, 1997
Volumetric measurement of human calf muscle from magnetic resonance imagingM A Elliott, G A Walter, H Gulish, et al.
Leukemia|May 13, 2005
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitroH G Jørgensen, E K Allan, S M Graham, et al.
Blood Cancer Journal|October 11, 2017
Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysisC L Haddox, A A Mangaonkar, D Chen, et al.
Leukemia|October 23, 2009
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survivalA Tefferi, T L Lasho, M M Patnaik, et al.
Leukemia Research|January 13, 2006
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literatureA Pardanani, R P Ketterling, C-Y Li, et al.
Molecular Psychiatry|October 17, 2012
Oral alprazolam acutely increases nucleus accumbens perfusionD H Wolf, A E Pinkham, T D Satterthwaite, et al.
British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Reproduction (Cambridge, England)|November 11, 2008
Effects of HSPA8, an evolutionarily conserved oviductal protein, on boar and bull spermatozoaRoslyn M A Elliott, Rhiannon E Lloyd, Alireza Fazeli, et al.
Bone Marrow Transplantation|July 16, 2008
Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancyL J Costa, V Rodriguez, L F Porrata, et al.
Magma (New York, N.Y.)|June 1, 1997
Volumetric measurement of human calf muscle from magnetic resonance imagingM A Elliott, G A Walter, H Gulish, et al.
Leukemia|May 13, 2005
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitroH G Jørgensen, E K Allan, S M Graham, et al.
Blood Cancer Journal|October 11, 2017
Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysisC L Haddox, A A Mangaonkar, D Chen, et al.
Leukemia|October 23, 2009
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survivalA Tefferi, T L Lasho, M M Patnaik, et al.
Leukemia Research|January 13, 2006
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literatureA Pardanani, R P Ketterling, C-Y Li, et al.
Molecular Psychiatry|October 17, 2012
Oral alprazolam acutely increases nucleus accumbens perfusionD H Wolf, A E Pinkham, T D Satterthwaite, et al.
British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Pageof 10